MedTrace Logo

Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention

NCT03048019 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-12-11

Study results available
· View outcomes & findings →

Summary

Immediate potent inhibition of platelet function is critical for the prevention of periprocedural ischemic event occurrences in high risk N-ST segment elevation myocardial infarction (NSTEMI) in patients undergoing percutaneous coronary intervention (PCI). Currently, dual antiplatelet therapy with aspirin and an oral P2Y12 receptor blocker (with loading doses) is widely used for PCI. However, immediate, potent and reversible inhibition of platelet aggregation is not possible even with the newer oral agents, prasugrel and ticagrelor. Therefore, an intravenously administered GPIIb/IIIa receptor inhibitor (tirofiban) or P2Y12 receptor blocker (cangrelor) with fast onset and offset of actions will provide more desired antiplatelet effects in the setting of PCI. This study will measure and compare the anti-platelet effects of Tirofiban and Cangrelor in patients presenting with N-STEMI and undergoing PCI.

Conditions

  • Non-ST Elevation Myocardial Infarction (NSTEMI)

Interventions

DRUG

Tirofiban

Patients will receive Tirofiban during the PCI procedure

DRUG

Cangrelor

Patients will receive Cangrelor during the PCI procedure

Sponsors & Collaborators

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Paul Gurbel, MD · Inova Health Care Services

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-23
Primary Completion
2019-06-27
Completion
2019-06-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03048019 on ClinicalTrials.gov